Final Analysis of PALLAS Shows No Benefit With Palbociclib Plus Endocrine Therapy in Early Breast Cancer
Palbociclib added to adjuvant endocrine therapy failed to improve iDFS.
Palbociclib added to adjuvant endocrine therapy failed to improve iDFS.
The cumulative incidence of bone fractures was below 5% in BPA recipients.
Researchers identified risk factors for distant metastasis in sporadic and hereditary medullary thyroid cancer.
The single-center study evaluated 119 consecutive patients with LAPC who underwent A-RT from 2016 to 2019.